article thumbnail

Agena Bioscience Granted EUA for High-Throughput, Low-Cost SARS-CoV-2 Panel

The Pharma Data

.” With the panel’s authorization, Agena also aims to alleviate material shortages, enabling laboratories to accelerate testing without concerns about instrument or reagent availability. Agena Bioscience develops, manufactures, and supplies genetic analysis systems and reagents, including the MassARRAY ® System.

article thumbnail

Top 10 Biotech Trends for 2025

XTalks

Biomanufacturing and Automation The production of vaccines, drugs and diagnostic reagents increasingly depends on good manufacturing practice (GMP) facilities for the manufacturing of critical reagents, a reliance that has intensified since the pandemic. percent from 2021 to 2031, reaching an estimated value of $85.2 billion by 2031.